Molecular mechanism of gossypol mediating CCL2 and IL‑8 attenuation in triple‑negative breast cancer cells
- Authors:
- Samia S. Messeha
- Najla O. Zarmouh
- Patricia Mendonca
- Carolyn Cotton
- Karam F.A. Soliman
-
Affiliations: Division of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA - Published online on: June 15, 2020 https://doi.org/10.3892/mmr.2020.11240
- Pages: 1213-1226
-
Copyright: © Messeha et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI | |
Aggarwal BB: Nuclear factor-kappaB: The enemy within. Cancer Cell. 6:203–208. 2004. View Article : Google Scholar : PubMed/NCBI | |
Balkwill F and Mantovani A: Inflammation and cancer: Back to virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI | |
Kuper H, Adami HO and Trichopoulos D: Infections as a major preventable cause of human cancer. J Intern Med. 248:171–183. 2000. View Article : Google Scholar : PubMed/NCBI | |
Balkwill F: TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 25:409–416. 2006. View Article : Google Scholar : PubMed/NCBI | |
Fang WB, Yao M, Brummer G, Acevedo D, Alhakamy N, Berkland C and Cheng N: Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment. Oncotarget. 7:49349–49367. 2016. View Article : Google Scholar : PubMed/NCBI | |
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI | |
Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM and Bhargava R: Androgen receptor in breast cancer: Expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 23:205–212. 2010. View Article : Google Scholar : PubMed/NCBI | |
Anders CK and Carey LA: Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2 (Suppl 2):S73–S81. 2009. View Article : Google Scholar | |
Albain KS, Unger JM, Crowley JJ, Coltman CA Jr and Hershman DL: Racial disparities in cancer survival among randomized clinical trials patients of the Southwest oncology group. J Natl Cancer Inst. 101:984–992. 2009. View Article : Google Scholar : PubMed/NCBI | |
Beaumont T and Leadbeater M: Treatment and care of patients with metastatic breast cancer. Nurs Stand. 25:49–56. 2011. View Article : Google Scholar : PubMed/NCBI | |
Fernandez Y, Cueva J, Palomo AG, Ramos M, de Juan A, Calvo L, García-Mata J, García-Teijido P, Peláez I and García-Estévez L: Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev. 36:33–42. 2010. View Article : Google Scholar : PubMed/NCBI | |
Liu P, Kumar IS, Brown S, Kannappan V, Tawari PE, Tang JZ, Jiang W, Armesilla AL, Darling JL and Wang W: Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Br J Cancer. 109:1876–1885. 2013. View Article : Google Scholar : PubMed/NCBI | |
Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, et al: Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther. 12:104–116. 2013. View Article : Google Scholar : PubMed/NCBI | |
Allavena P, Garlanda C, Borrello MG, Sica A and Mantovani A: Pathways connecting inflammation and cancer. Curr Opin Genet Dev. 18:3–10. 2008. View Article : Google Scholar : PubMed/NCBI | |
Candido J and Hagemann T: Cancer-related inflammation. J Clin Immunol. 33 (Suppl 1):S79–S84. 2013. View Article : Google Scholar : PubMed/NCBI | |
Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K and Toi M: Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer. 92:1085–1091. 2001. View Article : Google Scholar : PubMed/NCBI | |
Bieche I, Chavey C, Andrieu C, Busson M, Vacher S, Corre LL, Guinebretière JM, Burlinchon S, Lidereau R and Lazennec G: CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer. 14:1039–1052. 2007. View Article : Google Scholar : PubMed/NCBI | |
Fang WB, Jokar I, Zou A, Lambert D, Dendukuri P and Cheng N: CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms. J Biol Chem. 287:36593–36608. 2012. View Article : Google Scholar : PubMed/NCBI | |
Perrot-Applanat M, Vacher S, Toullec A, Pelaez I, Velasco G, Cormier F, El Sheikh Saad H, Lidereau R, Baud V and Bièche I: Similar NF-kB gene signatures in TNF-α treated human endothelial cells and breast tumor biopsies. PLoS One. 6:e215892011. View Article : Google Scholar : PubMed/NCBI | |
Leek RD, Landers R, Fox SB, Ng F, Harris AL and Lewis CE: Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer. 77:2246–2251. 1998. View Article : Google Scholar : PubMed/NCBI | |
Wang N, Liang H and Zen K: Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol. 5:6142014. View Article : Google Scholar : PubMed/NCBI | |
Yin Y, Chen X and Shu Y: Gene expression of the invasive phenotype of TNF-alpha-treated MCF-7 cells. Biomed Pharmacother. 63:421–428. 2009. View Article : Google Scholar : PubMed/NCBI | |
Voss V, Senft C, Lang V, Ronellenfitsch MW, Steinbach JP, Seifert V and Kögel D: The pan-Bcl-2 inhibitor (−)-gossypol triggers autophagic cell death in malignant glioma. Mol Cancer Res. 8:1002–1016. 2010. View Article : Google Scholar : PubMed/NCBI | |
Bromberg J: Stat proteins and oncogenesis. J Clin Invest. 109:1139–1142. 2002. View Article : Google Scholar : PubMed/NCBI | |
Dreesen O and Brivanlou AH: Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev. 3:7–17. 2007. View Article : Google Scholar : PubMed/NCBI | |
Zubair A and Frieri M: Role of nuclear factor-kB in breast and colorectal cancer. Curr Allergy Asthma Rep. 13:44–49. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zhong S, Leong J, Ye W, Xu P, Lin SH, Liu JY and Lin YC: (−)-Gossypol-enriched cottonseed oil inhibits proliferation and adipogenesis of human breast pre-adipocytes. Anticancer Res. 33:949–955. 2013.PubMed/NCBI | |
Cao H, Sethumadhavan K and Bland JM: Isolation of cottonseed extracts that affect human cancer cell growth. Sci Rep. 8:104582018. View Article : Google Scholar : PubMed/NCBI | |
He Z, Zhang H and Olk DC: Chemical composition of defatted cottonseed and soy meal products. PLoS One. 10:e01299332015. View Article : Google Scholar : PubMed/NCBI | |
Sharifi-Rad M, Fokou PVT, Sharopov F, Martorell M, Ademiluyi AO, Rajkovic J, Salehi B, Martins N, Iriti M and Sharifi-Rad J: Antiulcer agents: From plant extracts to phytochemicals in healing promotion. Molecules. 23:17512018. View Article : Google Scholar | |
Wang X, Howell CP, Chen F, Yin J and Jiang Y: Gossypol-a polyphenolic compound from cotton plant. Adv Food Nutr Res. 58:215–263. 2009. View Article : Google Scholar : PubMed/NCBI | |
Zhang M, Liu H, Guo R, Ling Y, Wu X, Li B, Roller PP, Wang S and Yang D: Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol. 66:93–103. 2003. View Article : Google Scholar : PubMed/NCBI | |
Pang X, Wu Y, Wu Y, Lu B, Chen J, Wang J, Yi Z, Qu W and Liu M: (−)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis. Mol Cancer Ther. 10:795–805. 2011. View Article : Google Scholar : PubMed/NCBI | |
Flack MR, Pyle RG, Mullen NM, Lorenzo B, Wu YW, Knazek RA, Nisula BC and Reidenberg MM: Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab. 76:1019–1024. 1993. View Article : Google Scholar : PubMed/NCBI | |
Moon DO, Kim MO, Lee JD and Kim GY: Gossypol suppresses NF-kappaB activity and NF-kappaB-related gene expression in human leukemia U937 cells. Cancer Lett. 264:192–200. 2008. View Article : Google Scholar : PubMed/NCBI | |
Benvenuto M, Mattera R, Masuelli L, Taffera G, Andracchio O, Tresoldi I, Lido P, Giganti MG, Godos J, Modesti A and Bei R: (±)-Gossypol induces apoptosis and autophagy in head and neck carcinoma cell lines and inhibits the growth of transplanted salivary gland cancer cells in BALB/c mice. Int J Food Sci Nutr. 68:298–312. 2017. View Article : Google Scholar : PubMed/NCBI | |
Moon DO, Choi YH, Moon SK, Kim WJ and Kim GY: Gossypol decreases tumor necrosis factor-α-induced intercellular adhesion molecule-1 expression via suppression of NF-κB activity. Food Chem Toxicol. 49:999–1005. 2011. View Article : Google Scholar : PubMed/NCBI | |
Gilbert NE, O'Reilly JE, Chang CJ, Lin YC and Brueggemeier RW: Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life Sci. 57:61–67. 1995. View Article : Google Scholar : PubMed/NCBI | |
Hu YF, Chang CJ, Brueggemeier RW and Lin YC: Gossypol inhibits basal and estrogen-stimulated DNA synthesis in human breast carcinoma cells. Life Sci. 53:PL433–PL438. 1993. View Article : Google Scholar : PubMed/NCBI | |
Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI | |
Yoshida R, Niki M, Jyotaki M, Sanematsu K, Shigemura N and Ninomiya Y: Modulation of sweet responses of taste receptor cells. Semin Cell Dev Biol. 24:226–231. 2013. View Article : Google Scholar : PubMed/NCBI | |
Cheng W, Zhao YQ, Li YM and Yang DJ: Effects of gossypol acetate on apoptosis in primary cultured cells from patients with lymphoid leukemia and its synergy with dexamethasone. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 20:229–234. 2012.(In Chinese). PubMed/NCBI | |
Baoleri X, Dong C, Zhou Y, Zhang Z, Lu X, Xie P and Li Y: Combination of L-gossypol and low-concentration doxorubicin induces apoptosis in human synovial sarcoma cells. Mol Med Rep. 12:5924–5932. 2015. View Article : Google Scholar : PubMed/NCBI | |
Karaca B, Atmaca H, Uzunoglu S, Karabulut B, Sanli UA and Uslu R: Enhancement of taxane-induced cytotoxicity and apoptosis by gossypol in human breast cancer cell line MCF-7. J BUON. 14:479–485. 2009.PubMed/NCBI | |
Zhao GX, Xu LH, Pan H, Lin QR, Huang MY, Cai JY, Ouyang DY and He XH: The BH3-mimetic gossypol and noncytotoxic doses of valproic acid induce apoptosis by suppressing cyclin-A2/Akt/FOXO3a signaling. Oncotarget. 6:38952–38966. 2015. View Article : Google Scholar : PubMed/NCBI | |
Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME and Collins-Burow BM: Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 14:R792012. View Article : Google Scholar : PubMed/NCBI | |
Sato N, Beitz JG, Kato J, Yamamoto M, Clark JW, Calabresi P, Raymond A and Frackelton Jr AR: Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol. 142:1119–1130. 1993.PubMed/NCBI | |
Messeha SS, Zarmouh NO, Mendonca P, Alwagdani H, Kolta MG and Soliman KFA: The inhibitory effects of plumbagin on the NF-kB pathway and CCL2 release in racially different triple-negative breast cancer cells. PLoS One. 13:e02011162018. View Article : Google Scholar : PubMed/NCBI | |
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI | |
Yamamoto H, Omelchenko I, Shi X and Nuttall AL: The influence of NF-kappaB signal-transduction pathways on the murine inner ear by acoustic overstimulation. J Neurosci Res. 87:1832–1840. 2009. View Article : Google Scholar : PubMed/NCBI | |
Gallelli L, Falcone D, Cannataro R, Perri M, Serra R, Pelaia G, Maselli R, Savino R, Spaziano G and D'Agostino B: Theophylline action on primary human bronchial epithelial cells under proinflammatory stimuli and steroidal drugs: A therapeutic rationale approach. Drug Des Dev Ther. 11:265–272. 2017. View Article : Google Scholar | |
Barba-Barajas M, Hernandez-Flores G, Lerma-Diaz JM, Ortiz-Lazareno PC, Domínguez-Rodríguez JR, Barba-Barajas L, de Celis R, Jave-Suarez LF, Aguilar-Lemarroy AC, Guevara-Barraza MG and Bravo-Cuellar A: Gossypol induced apoptosis of polymorphonuclear leukocytes and monocytes: Involvement of mitochondrial pathway and reactive oxygen species. Immunopharmacol Immunotoxicol. 31:320–330. 2009. View Article : Google Scholar : PubMed/NCBI | |
Anderson GM, Nakada MT and DeWitte M: Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 4:314–320. 2004. View Article : Google Scholar : PubMed/NCBI | |
Ma Y, Ren Y, Dai ZJ, Wu CJ, Ji YH and Xu J: IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients. Adv Clin Exp Med. 26:421–426. 2017. View Article : Google Scholar : PubMed/NCBI | |
John M, Au BT, Jose PJ, Lim S, Saunders M, Barnes PJ, Mitchell JA, Belvisi MG and Chung KF: Expression and release of interleukin-8 by human airway smooth muscle cells: Inhibition by Th-2 cytokines and corticosteroids. Am J Respir Cell Mol Biol. 18:84–90. 1998. View Article : Google Scholar : PubMed/NCBI | |
Grund EM, Kagan D, Tran CA, Zeitvogel A, Starzinski-Powitz A, Nataraja S and Palmer SS: Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells. Mol Pharmacol. 73:1394–1404. 2008. View Article : Google Scholar : PubMed/NCBI | |
An J, Xue Y, Long M, Zhang G, Zhang J and Su H: Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells. Oncotarget. 8:39230–39240. 2017. View Article : Google Scholar : PubMed/NCBI | |
Strieter RM, Wiggins R, Phan SH, Wharram BL, Showell HJ, Remick DC, Chensue SW and Kunkel SL: Monocyte chemotactic protein gene expression by cytokine-treated human fibroblasts and endothelial cells. Biochem Biophys Res Commun. 162:694–700. 1989. View Article : Google Scholar : PubMed/NCBI | |
Sticherling M, Hetzel F, Schroder JM and Christophers E: Time- and stimulus-dependent secretion of NAP-1/IL-8 by human fibroblasts and endothelial cells. J Invest Dermatol. 101:573–576. 1993. View Article : Google Scholar : PubMed/NCBI | |
Zachariae CO, Anderson AO, Thompson HL, Appella E, Mantovani A, Oppenheim JJ and Matsushima K: Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line. J Exp Med. 171:2177–2182. 1990. View Article : Google Scholar : PubMed/NCBI | |
Krupa A, Fol M, Dziadek BR, Kepka E, Wojciechowska D, Brzostek A, Torzewska A, Dziadek J, Baughman RP, Griffith D and Kurdowska AK: Binding of CXCL8/IL-8 to mycobacterium tuberculosis modulates the innate immune response. Mediators Inflamm. 2015:1247622015. View Article : Google Scholar : PubMed/NCBI | |
Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H and Matsushima K: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 6:3282–3289. 2000.PubMed/NCBI | |
Matsushima K, Larsen CG, DuBois GC and Oppenheim JJ: Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med. 169:1485–1490. 1989. View Article : Google Scholar : PubMed/NCBI | |
Espinoza-Sanchez NA, Chimal-Ramirez GK, Mantilla A and Fuentes-Panana EM: IL-1β, IL-8, and matrix metalloproteinases-1,-2, and −10 are enriched upon monocyte-breast cancer cell cocultivation in a matrigel-based three-dimensional system. Front Immunol. 8:2052017. View Article : Google Scholar : PubMed/NCBI | |
Nam JS, Kang MJ, Suchar AM, Shimamura T, Kohn EA, Michalowska AM, Jordan VC, Hirohashi S and Wakefield LM: Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res. 66:7176–7184. 2006. View Article : Google Scholar : PubMed/NCBI | |
Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA and Pollard JW: CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 475:222–225. 2011. View Article : Google Scholar : PubMed/NCBI | |
Tsuyada A, Chow A, Wu J, Somlo G, Chu P, Loera S, Luu T, Li XA, Wu X, Ye W, et al: CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 72:2768–2779. 2012. View Article : Google Scholar : PubMed/NCBI | |
Koury J, Zhong L and Hao J: Targeting signaling pathways in cancer stem cells for cancer treatment. Stem Cells Int. 2017:29258692017. View Article : Google Scholar : PubMed/NCBI | |
Pires BR, DE Amorim ÍS, Souza LD, Rodrigues JA and Mencalha AL: Targeting cellular signaling pathways in breast cancer stem cells and its implication for cancer treatment. Anticancer Res. 36:5681–5691. 2016. View Article : Google Scholar : PubMed/NCBI | |
Huth HW, Santos DM, Gravina HD, Resende JM, Goes AM, de Lima ME and Ropert C: Upregulation of p38 pathway accelerates proliferation and migration of MDA-MB-231 breast cancer cells. Oncol Rep. 37:2497–2505. 2017. View Article : Google Scholar : PubMed/NCBI | |
Peters RT, Liao SM and Maniatis T: IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex. Mol Cell. 5:513–522. 2000. View Article : Google Scholar : PubMed/NCBI | |
Bauer D, Redmon N, Mazzio E and Soliman KF: Apigenin inhibits TNFα/IL-1α-induced CCL2 release through IKBK-epsilon signaling in MDA-MB-231 human breast cancer cells. PLoS One. 12:e01755582017. View Article : Google Scholar : PubMed/NCBI | |
Williams V, Grosset AA, Zamorano Cuervo N, St-Pierre Y, Sylvestre MP, Gaboury L and Grandvaux N: Detection of IKKepsilon by immunohistochemistry in primary breast cancer: Association with EGFR expression and absence of lymph node metastasis. BMC Cancer. 17:3562017. View Article : Google Scholar : PubMed/NCBI | |
Guo JP, Shu SK, Esposito NN, Coppola D, Koomen JM and Cheng JQ: IKK phosphorylation of estrogen receptor α Ser-167 and contribution to tamoxifen resistance in breast cancer. J Biol Chem. 291:228572016. View Article : Google Scholar : PubMed/NCBI | |
Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, Gerald WL, Bornmann W and Bromberg JF: Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res. 9:R322007. View Article : Google Scholar : PubMed/NCBI | |
Li L and Shaw PE: Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines. J Biol Chem. 277:17397–17405. 2002. View Article : Google Scholar : PubMed/NCBI | |
Walker SR, Nelson EA, Zou L, Chaudhury M, Signoretti S, Richardson A and Frank DA: Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res. 7:966–976. 2009. View Article : Google Scholar : PubMed/NCBI | |
Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, et al: The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(−) stem cell-like breast cancer cells in human tumors. J Clin Invest. 121:2723–2735. 2011. View Article : Google Scholar : PubMed/NCBI | |
House CD, Grajales V, Ozaki M, Jordan E, Wubneh H, Kimble DC, James JM, Kim MK and Annunziata CM: IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts. BMC Cancer. 18:5952018. View Article : Google Scholar : PubMed/NCBI | |
Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, et al: Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 129:1065–1079. 2007. View Article : Google Scholar : PubMed/NCBI | |
Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, Hahn WC and Cantley LC: Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell. 34:461–472. 2009. View Article : Google Scholar : PubMed/NCBI | |
Barbie TU, Alexe G, Aref AR, Li S, Zhu Z, Zhang X, Imamura Y, Thai TC, Huang Y, Bowden M, et al: Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest. 124:5411–5423. 2014. View Article : Google Scholar : PubMed/NCBI | |
Qin B and Cheng K: Silencing of the IKKε gene by siRNA inhibits invasiveness and growth of breast cancer cells. Breast Cancer Res. 12:R742010. View Article : Google Scholar : PubMed/NCBI | |
Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J and Hortobágyi GN: High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. Oncologist. 17:766–774. 2012. View Article : Google Scholar : PubMed/NCBI | |
Seddighzadeh M, Zhou JN, Kronenwett U, Shoshan MC, Auer G, Sten-Linder M, Wiman B and Linder S: ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. Clin Exp Metastasis. 17:649–654. 1999. View Article : Google Scholar : PubMed/NCBI | |
Kyriakis JM and Avruch J: Mammalian MAPK signal transduction pathways activated by stress and inflammation: A 10-year update. Physiol Rev. 92:689–737. 2012. View Article : Google Scholar : PubMed/NCBI | |
Cargnello M and Roux PP: Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 75:50–83. 2011. View Article : Google Scholar : PubMed/NCBI | |
Samatar AA and Poulikakos PI: Targeting RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug Discov. 13:928–942. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wen S, Hou Y, Fu L, Xi L, Yang D, Zhao M, Qin Y, Sun K, Teng Y and Liu M: Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β3-p38 MAPK signalling. Cancer Lett. 442:320–332. 2019. View Article : Google Scholar : PubMed/NCBI | |
Liu Q, Li A, Tian Y, Wu JD, Liu Y, Li T, Chen Y, Han X and Wu K: The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth Factor Rev. 31:61–71. 2016. View Article : Google Scholar : PubMed/NCBI | |
Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpé S, Vermeulen PB and Dirix LY: Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 10:7157–7162. 2004. View Article : Google Scholar : PubMed/NCBI | |
Guo Y, Zang Y, Lv L, Cai F, Qian T, Zhang G and Feng Q: IL8 promotes proliferation and inhibition of apoptosis via STAT3/AKT/NFkB pathway in prostate cancer. Mol Med Rep. 16:9035–9042. 2017. View Article : Google Scholar : PubMed/NCBI | |
Snoussi K, Mahfoudh W, Bouaouina N, Ahmed SB, Helal AN and Chouchane L: Genetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinoma. Hum Immunol. 67:13–21. 2006. View Article : Google Scholar : PubMed/NCBI | |
Zuccari DA, Leonel C, Castro R, Gelaleti GB, Jardim BV, Moscheta MG, Regiani VR, Ferreira LC, Lopes JR, Neto Dde S and Esteves JL: An immunohistochemical study of interleukin-8 (IL-8) in breast cancer. Acta Histochem. 114:571–576. 2012. View Article : Google Scholar : PubMed/NCBI | |
Kim S, Jeon M, Lee JE and Nam SJ: MEK activity controls IL-8 expression in tamoxifen-resistant MCF-7 breast cancer cells. Oncol Rep. 35:2398–2404. 2016. View Article : Google Scholar : PubMed/NCBI | |
Kim S, You D, Jeong Y, Yu J, Kim SW, Nam SJ and Lee JE: Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells. Phytomedicine. 50:43–49. 2018. View Article : Google Scholar : PubMed/NCBI | |
Yao C, Lin Y, Chua MS, Ye CS, Bi J, Li W, Zhu YF and Wang SM: Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer. 121:1949–1957. 2007. View Article : Google Scholar : PubMed/NCBI | |
Park SH, Das BB, Casagrande F, Tian Y, Nothnagel HJ, Chu M, Kiefer H, Maier K, De Angelis AA, Marassi FM and Opella SJ: Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature. 491:779–783. 2012. View Article : Google Scholar : PubMed/NCBI | |
Singh JK, Simoes BM, Clarke RB and Bundred NJ: Targeting IL-8 signalling to inhibit breast cancer stem cell activity. Expert Opin Ther Targets. 17:1235–1241. 2013. View Article : Google Scholar : PubMed/NCBI | |
Singh JK, Simoes BM, Howell SJ, Farnie G and Clarke RB: Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 15:2102013. View Article : Google Scholar : PubMed/NCBI | |
Alfaro C, Teijeira A, Onate C, Pérez G, Sanmamed MF, Andueza MP, Alignani D, Labiano S, Azpilikueta A, Rodriguez-Paulete A, et al: Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin Cancer Res. 22:3924–3936. 2016. View Article : Google Scholar : PubMed/NCBI | |
Elliott CL, Allport VC, Loudon JA, Wu GD and Bennett PR: Nuclear factor-kappa B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells. Mol Hum Reprod. 7:787–790. 2001. View Article : Google Scholar : PubMed/NCBI | |
Wang L, Tang C, Cao H, Li K, Pang X, Zhong L, Dang W, Tang H, Huang Y, Wei L, et al: Activation of IL-8 via PI3K/Akt-dependent pathway is involved in leptin-mediated epithelial-mesenchymal transition in human breast cancer cells. Cancer Biol Ther. 16:1220–1230. 2015. View Article : Google Scholar : PubMed/NCBI | |
Lian S, Xia Y, Ung TT, Khoi PN, Yoon HJ, Kim NH, Kim KK and Jung YD: Carbon monoxide releasing molecule-2 ameliorates IL-1β-induced IL-8 in human gastric cancer cells. Toxicology 361–362. 24–38. 2016. View Article : Google Scholar | |
Singh RK, Gutman M, Radinsky R, Bucana CD and Fidler IJ: Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res. 54:3242–3247. 1994.PubMed/NCBI | |
Fernando RI, Hamilton DH, Dominguez C, David JM, McCampbell KK and Palena C: IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib. Oncotarget. 7:42031–42044. 2016. View Article : Google Scholar : PubMed/NCBI | |
Jiang P, Enomoto A, Jijiwa M, Kato T, Hasegawa T, Ishida M, Sato T, Asai N, Murakumo Y and Takahashi M: An actin-binding protein girdin regulates the motility of breast cancer cells. Cancer Res. 68:1310–1318. 2008. View Article : Google Scholar : PubMed/NCBI | |
Lin C, Ear J, Pavlova Y, Mittal Y, Kufareva I, Ghassemian M, Abagyan R, Garcia-Marcos M and Ghosh P: Tyrosine phosphorylation of the Gα-interacting protein GIV promotes activation of phosphoinositide 3-kinase during cell migration. Sci Signal. 4:ra642011. View Article : Google Scholar : PubMed/NCBI | |
Ni W, Fang Y, Tong L, Tong Z, Yi F, Qiu J, Wang R and Tong X: Girdin regulates the migration and invasion of glioma cells via the PI3K-Akt signaling pathway. Mol Med Rep. 12:5086–5092. 2015. View Article : Google Scholar : PubMed/NCBI | |
Romashkova JA and Makarov SS: NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 401:86–90. 1999. View Article : Google Scholar : PubMed/NCBI | |
Jiang BH and Liu LZ: PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta. 1784:150–158. 2008. View Article : Google Scholar : PubMed/NCBI | |
Abraham RT: Chemokine to the rescue: Interleukin-8 mediates resistance to PI3K-pathway-targeted therapy in breast cancer. Cancer Cell. 22:703–705. 2012. View Article : Google Scholar : PubMed/NCBI | |
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
Darnell JE: Validating Stat3 in cancer therapy. Nat Med. 11:595–596. 2005. View Article : Google Scholar : PubMed/NCBI | |
Subramaniam A, Shanmugam MK, Perumal E, Li F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar AP, Tan BKH, et al: Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta. 1835:46–60. 2013.PubMed/NCBI | |
Rajendran P, Li F, Shanmugam MK, Kannaiyan R, Goh JN, Wong KF, Wang W, Khin E, Tergaonkar V, Kumar AP, et al: Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev Res (Phila). 5:631–643. 2012. View Article : Google Scholar : PubMed/NCBI | |
Samson ME, Porter NG, Hurley DM, Adams SA and Eberth JM: Disparities in breast cancer incidence, mortality, and quality of care among African American and European American women in South Carolina. South Med J. 109:24–30. 2016. View Article : Google Scholar : PubMed/NCBI |